Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Appointed director
Quarterly results
Director departure
ACHILLION PHARMACEUTICALS INC (ACHN) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/28/2020 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Achillion Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Achillion Pharmaceuticals, Inc"
01/24/2020 8-K Other Events
01/16/2020 8-K Other Events
12/19/2019 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $0.001 per share ACHN Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined i...",
"Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update"
10/16/2019 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "Agreement and Plan of Merger, by and among Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Beagle Merger Sub, Inc",
"Amendment to Achillion's Amended and Restated By-Laws",
"Alexion to Acquire Achillion"
09/17/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $0.001 per share ACHN Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined i..."
08/08/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update"
06/03/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Achillion Pharmaceuticals, Inc",
"Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Achillion Pharmaceuticals, Inc"
05/17/2019 8-K Investor presentation
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, Par Value $0.001 per share ACHN Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Ru...",
"Presentation",
"Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting"
05/09/2019 8-K Quarterly results
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected ...",
"Achillion Reports First Quarter 2019 Financial Results"
03/07/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Achillion Reports Fourth Quarter and Full Year 2018 Financial Results"
02/11/2019 8-K Quarterly results
12/18/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elec..."
12/04/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "N/A",
"Lease Agreement, by and between Achillion Pharmaceuticals, Inc. and Sentry KPG III, L.P",
"Amendment to Lease, by and between Achillion Pharmaceuticals, Inc. and Sentry KPG III, L.P"
11/21/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SIGNATURE",
"Letter Agreement, by and between Achillion Pharmaceuticals, Inc. and Mary Kay Fenton"
11/07/2018 8-K Quarterly results
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2018 Achillion Pharmaceuticals, Inc. Delaware 001-33095 52-2113479 300 George Street New Haven, CT 06511 Registrant's telephone number, including area code: 624-7000 N/A Check the appropriate box if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act . ☐ Pre-commencement communications pursuant to Rule 14a-2 under the Exchange Act )",
"ACHILLION REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS"
09/10/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between Achillion Pharmaceuticals, Inc. and Paul Firuta",
"Employment Agreement, by and between Achillion Pharmaceuticals, Inc. and Paul Firuta"
08/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"ACHILLION REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS"
06/01/2018 8-K Submission of Matters to a Vote of Security Holders
Docs: "FORM 8-K"
05/02/2018 8-K Quarterly results
Docs: "FORM 8-K",
"ACHILLION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND MANAGEMENT TRANSITION"
02/22/2018 8-K Quarterly results
Docs: "ACHILLION ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY; ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS"
12/15/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
11/16/2017 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "FORM 8-K",
"Underwriting Agreement, by and among the Company, Goldman Sachs & Co. LLC and Leerink Partners LLC, as representatives of the underwriters named therein and Johnson & Johnson Innovation-JJDC, Inc., as selling stockholder",
"Letter Agreement, by and between the Company and Johnson & Johnson Innovation-JJDC, Inc",
"ACHILLION ANNOUNCES PROPOSED SECONDARY OFFERING OF COMMON STOCK",
"ACHILLION ANNOUNCES PRICING OF SECONDARY OFFERING OF COMMON STOCK"
11/14/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"ACHILLION REPORTS PRELIMINARY PROOF-OF-CONCEPT WITH ACH-4471 FOR THE TREATMENT OF C3G"
11/01/2017 8-K Quarterly results
Docs: "FORM 8-K",
"ACHILLION REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS"
09/11/2017 8-K Quarterly results
09/11/2017 8-K Quarterly results
08/08/2017 8-K Quarterly results
Docs: "FORM 8-K",
"ACHILLION REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND PROOF-OF-CONCEPT WITH A FIRST-IN-CLASS, ORAL FACTOR D INHIBITOR"
07/10/2017 8-K Form 8-K - Current report:
05/24/2017 8-K Form 8-K - Current report
05/04/2017 8-K Form 8-K - Current report
02/23/2017 8-K Form 8-K - Current report
12/28/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy